Q4 2024 Earnings Call Transcript February 11, 2025 Arvinas, Inc. beats earnings expectations. Reported EPS is $-0.63, ...

Significant negative correlations between mRNAsi and STING gene expression levels were found in AML, CHL, CLL, CML, DLBCL, MCL, MDS, MM, pre-B cell acute lymphoblastic leukemias (pre-B-ALL), PTCLNOS, ...

We describe two patients in whom malignant monoclonal T-cell lymphoproliferation developed after administration of chimeric antigen receptor (CAR) T-cell therapy with ciltacabtagene autoleucel ...

According to the classical paradigm, CCR7 is a homing chemokine receptor that grants normal lymphocytes access to secondary lymphoid tissues such as lymph nodes or spleen. As such, in most ...

48 Common lymphoma subtypes that trigger HLH include NK cell–T-cell lymphoma, angioimmunoblastic T-cell lymphoma, subcutaneous panniculitis-like T-cell non-Hodgkin’s lymphoma, and ...

These data show the promise of ARV-393 as a monotherapy in angioimmunoblastic T-cell lymphoma patient-derived in vivo models. Additionally, we will show ARV-393 in combination with standard of ...

We produce expert, up-to-date and high-quality information for people affected by lymphoma. Our information is based on the latest evidence and is reviewed every 2 to 3 years. It is written in plain ...

PTCL 的主要类型包括血管免疫母细胞性 T 细胞淋巴瘤（AITL，angioimmunoblastic T-cell lymphoma ）15 例（32%）、间变性大细胞淋巴瘤（ALCL，anaplastic large cell lymphoma ）12 例（26%）和外周 T 细胞淋巴瘤非特指型（PTCL-NOS，peripheral T-cell lymphoma not other ...

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS® (brentuximab vedotin) in combination with ...

Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma: New York Friday, February 14, 2025, 11:00 Hrs [IST] Pfizer ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application ...